Company profile
EIKON THERAPEUTICS, INC.
NASDAQ:EIKNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RESIQUIMOD SULFATE | phase2_3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06253130 | phase1_2 | recruiting | 2023-12-11 | 2027-06-01 | Eikon Therapeutics | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors |
| NCT06246110 | phase2 | active_not_recruiting | 2024-02-06 | 2026-12-01 | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
| NCT07365319 | phase2_3 | recruiting | 2026-06-15 | 2035-12-31 | Eikon Therapeutics | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. |
| NCT06907043 | phase1_2 | recruiting | 2025-04-30 | 2028-12-01 | Eikon Therapeutics | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. |
| NCT03486301 | phase1 | completed | 2018-02-15 | 2024-03-31 | Eikon Therapeutics | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab |
FDA applications (0)
No records yet.